Artificial Intelligence

At CES 2026, Jinxin Technology unveiled NAMI INSIGHT One, AI-powered learning glasses aiming to revolutionize education. But can it overcome the hurdles?

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

With a new $1.6B valuation led by T. Rowe Price, Hadrian is scaling its AI-powered factories to spearhead America's industrial and defense resurgence.

Amid rising regulatory pressure, dxFeed's flawless performance in a critical industry-wide disaster recovery test sets a new benchmark for data reliability.

A new collaboration between the Global Alzheimer's Platform and Alamar Biosciences aims to revolutionize diagnosis with ultra-sensitive blood tests for all.

The strategic acquisition combines computer vision with spatial intelligence, aiming to make advanced in-store analytics an accessible, essential tool for retailers.

NCR Voyix is launching a new AI-driven, microservices-based platform designed to help restaurants combat labor shortages and meet rising customer expectations.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

With a major investment from Santé Ventures, Brado AI is deploying conversational AI to guide patients and ease provider burdens. Here’s what it means.

With 11 straight quarters of growth and a focus on 'Physical AI,' lidar leader Ouster is set to detail its ambitious strategy for institutional investors.

A new partnership makes Eli Lilly's powerful AI models available to smaller firms via Revvity's platform, aiming to accelerate innovation with federated learning.

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

As Mammoth Biosciences preps for JPM, its ultracompact CRISPR tech aims to redefine in vivo gene therapy, promising cures for diseases beyond the liver.

Lightspeed's new conversational AI acts as a business partner for retailers and restaurants, turning complex data into simple answers to boost performance.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.